

**BIOGRAPHICAL SKETCH**  
**Complete for each professional associated with the project**

**Education**

[Begin with baccalaureate or other professional education and include postdoctoral training]

Institution and Location	Degree	Year Conferred	Field of Study
University of Verona	MD	1997	Research Thesis: Topographic study of paroxysmal elements in occipital spike-wave epilepsy of the adult.
University of Verona	Neurologist	2002	Research Thesis: Prognostic value of Tau and 14-3-3 proteins in CSF of multiple sclerosis patients

## Research and Professional Experience

[List in chronological order, previous employment, experience and honors]

### Positions and Honors

2002 – to date: resident Neurologist at the Multiple Sclerosis Center Spedali Civili of Brescia, Presidio di Montichiari.

2008: “Team Project” of AISM: visit at “The Shapiro Center for multiple sclerosis at the Minneapolis Clinic of Neurology”, Minnesota (U.S.A.).

2004- to date: EDSS Neurostatus qualification.

2004- to date: evaluating physician in several phase II and III clinical trials on Multiple Sclerosis.

## Publications

For each investigator, provide complete bibliographic citations for selected **publications related to the topic of this application**. DO NOT exceed one page for each individual.

1. Tau protein and 14-3-3-protein in the cerebrospinal fluid (CSF) of patients with multiple sclerosis. M.D. Benedetti, **C. Cordioli**, S. Rasia, S. Ottaviani, M.A. Bonometti, M. Fiorini, G. Zanusso, N. Rizzuto, S. Monaco. *Eur J Neurol* 10 (suppl 1), 101.
2. Mitoxantrone in Multiple Sclerosis: an eleven years experience. **C. Cordioli**, E. Cattaneo, R. Capra. *Neurol Sci*; supplement vol 24 october 2003, S 192.
3. Mitoxantrone in multiple sclerosis: short and long-term effectiveness-tolerability profile in 76 patients. **C. Cordioli**, C. Pezzotti, E. Cattaneo, R. Capra. *J Neurol* vol 252, june 2005, suppl 2.
4. Anti-GD2-like IgM autoreactivity in multiple sclerosis patients. S. Marconi, M. Acler, L. Lovato, L. De Toni, E. Tedeschi, E. Anghileri, S. Romito, **C. Cordioli**, B. Bonetti. *Multiple Sclerosis* 2006; 12:1-7
5. Assessment of INF $\beta$  bioavailability in multiple sclerosis treated patients: MxA mRNA versus antibody-detecting assays. R. Capra, **C. Cordioli**, A. Sottini, D. Monza, R. Bergamaschi, L. Imberti. *Neurology* 66 (5), march 2006 (suppl 2); A237.
6. MR imaging assessment of brain and cervical cord damage in patients with neuroborreliosis. F. Agosta, M.A. Rocca, B. Benedetti, R. Capra, **C. Cordioli**, M. Filippi. *American Journal of Neuroradiology*, april 2006, 27: 892-94.
7. Assessment of INF $\beta$  bioavailability in multiple sclerosis treated patients: MxA mRNA versus antibody-detecting assays. R. Capra, **C. Cordioli**, A. Sottini, D. Monza, R. Bergamaschi, L. Imberti. *Journal of Neurology*, vol 253 suppl. 2, may 2006. II/58: P228.
8. Analysis of incidence, risk factors and prognosis of acute promyelocytic leukaemia related to mitoxantrone therapy in multiple sclerosis patients. **C. Cordioli**, C. Cattaneo, G. Rossi, R. Capra. *Neurology* 2007; 68 (suppl 1): A276.
9. INF $\beta$  bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. R. Capra, A. Sottini, **C. Cordioli**, F. Serana, M. Chiarini, L. Caimi, A. Padovani, R. Bergamaschi, L. Imberti. *Journal of Neuroimmunology* 189 (2007) 102–110.
10. Changes in vitamin B12 and tumor necrosis factor- $\alpha$  levels in cerebrospinal fluid of patients with different subtypes of multiple sclerosis. G. Scalabrino, D. Galimberti, D. Scalabrini, F. Bamonti, D. Veber, E. Mutti, M. Carpo, M. De Riz, R. Capra, **C. Cordioli**, E. Scarpini. *Journal of Neurology*, vol 254 (suppl 3, may 2007): P529.
11. Interferon receptor isoforms in multiple sclerosis patients divided according to MxA mRNA induction by IFN beta. A. Sottini, R. Capra, C. Ghidini, F. Serana, M. Valotti, M. Chiarini, C. Zanotti, **C. Cordioli**, L. Caimi, L. Imberti. *Multiple Sclerosis*, 13 (suppl 2) october 2007, S63.
12. Modulation of IFNAR1 mRNA expression in multiple sclerosis patients. R. Capra, A. Sottini, C. Ghidini, F. Serana, M. Valotti, M. Chiarini, C. Zanotti, S. Rasia, **C. Cordioli**, L. Caimi, L. Imberti. *Neurology* 70 (11), 2008 (Suppl 1): A380.
13. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: The FEMIMS study. Cocco, E., Sardu, C., Gallo, P., Capra, R., Amato, M.P., Trojano, M., Uccelli, A., Marrosu, M.G., Galeotti, M., **Cordioli, C.**, Massole, S., Musu, L., Coghe, G., Patti, F., Lugaresi, A., Tola, M.R., Zipoli, V., Mancardi, G.L., Capello, E., Solaro, C., Caputo, C., Cavarretta, R., Merelli, E., Perini, P., Francia, A., Batocchi, A.P., Bergamaschi, R., Tavazzi, E., Cavalla, P., Masera, S., Bertolotto, A., Capobianco, M., Zorzon, M., Ghezzi, A., Zaffaroni, M. *Multiple Sclerosis*, volume 14, issue 9, year 2008, pp. 1225 – 1233.
14. Analysis of prevalence, risk factors and prognosis of acute myeloid leukemia secondary to mitoxantrone therapy in multiple sclerosis patients. **C. Cordioli**, N. De Rossi, S. Rasia, E. Cottini, C. Cattaneo, G. Rossi, R. Capra. *Journal of Neurology*, vol 255 (suppl 2, june 2008); 45: O190.
15. Increased production of new T-lymphocytes after Copaxone Therapy. M. Chiarini, R. Capra, A. Sottini, C. Ghidini, C. Zanotti, F. Serana, **C. Cordioli**, M. Rottoli, M. Zaffaroni, L. Imberti. *Journal of Neurology* vol 255 (suppl 2, june 2008); 143: P579.
16. Modulation of IFNAR1 mRNA expression in multiple sclerosis patients. Serana F, Sottini A, Ghidini C, Zanotti C, Capra R, **Cordioli C**, Caimi L, Imberti L. *J Neuroimmunol*. 2008 Jul;197(1):54-62. Epub 2008 May 15.
17. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis. De Stefano N, Filippi M, Hawkins C, Rózsa C, Kanta E, Lehel G, et al, Bergamaschi R, Bastianello S, Cosi V, **Cordioli C** et al (9011 study group). *J Neurol Sci*. 2008 Mar 15;266(1-2):44-50. Epub 2007 Sep 25.
18. T Cell renewal in glatiramer acetate-treated multiple sclerosis patients. M. Chiarini, R. Capra, A. Sottini, F. Serana, C. Ghidini, C. Zanotti, **C. Cordioli**, M. Rottoli, M. Zaffaroni, L. Imberti. *Neurology* 72 (11), 2009 (Suppl 3): A36.
19. Neuropsychological improvement after natalizumab therapy in MS: 1 year follow-up. F. Mattioli, C. Stampatori, C. Cordioli, S. Rasia, R. Capra. *J Neurol (suppl)* vol 30, november 2009: S310.
20. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate. Chiarini M, Sottini A, Ghidini C, Zanotti C, Serana F, Rottoli M, Zaffaroni M, Bergamaschi R, **Cordioli C**, Capra R, Imberti L. *Mult Scler*. 2010 Feb;16(2):218-27.
21. Shock cardiogeno all'esordio di sclerosi multipla in maschio di 13 anni. Molinaro A, Zonno G, Milesi G, Cordioli C, Micheli R, Fazzi E. *SINPIA*, Pisa 11-14 maggio 2011; Abstract Book P23, pag. 83.
22. Thyroid autoimmunity and dysfunction in relapsing remitting multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate. G. Frisullo, P. Annovazzi, B. Bodini, L. Boffa, M. Calabrese, E. Cocco, **C. Cordioli** et al. *Neurological Sciences*, supplement vol 32, october 2011, S 216.

23. Progressive multifocal leucoencephalopathy (PML) in natalizumab treated patient for multiple sclerosis: diagnosis and follow-up. S. Rasia, **C. Cordioli**, N. De Rossi, R. Capra. *Neurological Sciences*, supplement vol 32, october 2011, S 489.
24. Safety and efficacy of natalizumab infusions every eight weeks after a 24-month period of monthly infusions in multiple sclerosis patients. **C. Cordioli**, S. Rasia, N. De Rossi, F. Serana, R. Capra. *Multiple Sclerosis Journal* 2011; 17: S195.
25. Management of natalizumab-related PML: a different approach. **C. Cordioli**, C. Costanzi, N. De Rossi, S. Rasia, R. Capra. *Multiple Sclerosis Journal* 2012; 18: (S4) 279–508. P998.
26. MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients. F Serana, L Imberti, MP Amato, G Comi, C Gasperini, A Ghezzi, V Martinelli, L Provinciali, MR Rottoli, S Sotgiu, S Stecchi, M Vecchio, M Zaffaroni, **C Cordioli**, R Capra. *PLoS ONE* 2014, 9(4): e94794. DOI:10.1371.
27. Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patients. **C Cordioli**, N De Rossi, S Rasia, G Lodoli, R Capra. *Neurol Sci*. Aug 2014. ISSN 1590-1874. DOI 10.1007/s10072-014-1918-y.
28. The diagnosis of multiple sclerosis: pinpointing the concept of “no better explanation”. M Calabrese, C Gasperini, C Tortorella, S Malucchi, P Ragonese, G De Luca, R Fantozzi, S Lo Fermo, L Boffa, D Paolicelli, A Gajofatto, I Pesci, P Annovazzi, **C Cordioli**, et Al. *Multiple Sclerosis Journal* 2014; 20: (S1) 67-284.
29. Natalizumab to Fingolimod Switching in Multiple Sclerosis: Results from a “Real World” Retrospective Analysis. Rasia S, **Cordioli C**, De Rossi N, Pimazzoni F, Scarpazza C, L. Imberti, R. Capra. *J Mult Scler* 2015; 2:142.
30. Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene. Bertoli D, Serana F, Sottini A, **Cordioli C**, Maimone D, Amato MP, Centonze D, Florio C, Puma E, Capra R, Imberti L. *PLoS One*. 2015 Aug 18;10(8):e0135441. doi: 10.1371/journal.pone.0135441.
31. Bilateral visual loss recovering after tadalafil withdrawal. **C. Cordioli**, R. Capra. *Neurological Sciences*. May 2016, Volume 37, Issue 5, pp 809-810. First online: 23 December 2015.
32. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis. L Prosperini, F Saccà, **C Cordioli**, A Cortese, F Buttari, S Pontecorvo, A Bianco, S Ruggieri, S Haggiag, V Brescia Morra, R Capra, et Al. *Journal of Neurology*. February 2017, Volume 264, Issue 2, pp 284–294.
33. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. R Capra, **C Cordioli**, S Rasia, F Gallo, A Signori, MP Sormani. *Multiple Sclerosis Journal*. *Mult Scler*. 2017 Jan 1-5.
34. Age as a risk factor for early of natalizumab-related progressive multifocal leukoencephalopathy. L Prosperini, C Scarpazza, L. Imberti, **C. Cordioli**, N De Rossi, R. Capra. *J neurovirol*, DOI 10.1007/s13365-017-0561-9.

**Firma**

---

